IDEXX LABORATORIES INC /DE Sales Commissions and Fees
IDEXX LABORATORIES INC /DE (IDXX) reported Sales Commissions and Fees of $1.90 million for the 3-month period ending 2026-06-30, per its 10-Q filed 2026-08-04.
Financial Statements › Expense Statement › Operating Expenses
us-gaap:SalesCommissionsAndFees · last filed 2026-08-04
- IDEXX LABORATORIES INC /DE sales commissions and fees for the quarter ending 2026-06-30 was $1.90M, a 5.56% increase year-over-year.
- IDEXX LABORATORIES INC /DE sales commissions and fees for the quarter ending 2026-03-31 was $2.10M, a 16.67% increase year-over-year.
- IDEXX LABORATORIES INC /DE sales commissions and fees for the quarter ending 2025-12-31 was $1.60M, a 6.67% increase year-over-year.
- IDEXX LABORATORIES INC /DE sales commissions and fees for the quarter ending 2025-09-30 was $1.70M, a 6.25% increase year-over-year.
- IDEXX LABORATORIES INC /DE sales commissions and fees for fiscal 2025 was $6.90M, a 6.15% increase from fiscal 2024.
- IDEXX LABORATORIES INC /DE sales commissions and fees for fiscal 2024 was $6.50M, a 0.00% change from fiscal 2023.
- IDEXX LABORATORIES INC /DE sales commissions and fees for fiscal 2023 was $6.50M, a 0.00% change from fiscal 2022.
- IDEXX LABORATORIES INC /DE sales commissions and fees for fiscal 2022 was $6.50M, a 14.04% increase from fiscal 2021.
| Period end | Sales Commissions and Fees 3 month | Sales Commissions and Fees 6 month | Sales Commissions and Fees 9 month | Sales Commissions and Fees 12 month |
|---|---|---|---|---|
| 2026-06-30 | $1.90M 10-Q · filed 2026-08-04 | $4.00M 10-Q · filed 2026-08-04 | $5.60M derived: sum of 3 quarters · filed 2026-08-04 | $7.30M derived: sum of 4 quarters · filed 2026-08-04 |
| 2026-03-31 | $2.10M 10-Q · filed 2026-05-05 | $3.70M derived: sum of 2 quarters · filed 2026-05-05 | $5.40M derived: sum of 3 quarters · filed 2026-05-05 | $7.20M derived: sum of 4 quarters · filed 2026-08-04 |
| 2025-12-31 | $1.60M derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-20 | $3.30M derived: sum of 2 quarters · filed 2026-02-20 | $5.10M derived: sum of 3 quarters · filed 2026-08-04 | $6.90M 10-K · filed 2026-02-20 |
| 2025-09-30 | $1.70M 10-Q · filed 2025-11-03 | $3.50M derived: sum of 2 quarters · filed 2026-08-04 | $5.30M 10-Q · filed 2025-11-03 | $6.80M derived: sum of 4 quarters · filed 2026-08-04 |
| 2025-06-30 | $1.80M 10-Q · filed 2026-08-04 | $3.60M 10-Q · filed 2026-08-04 | $5.10M derived: sum of 3 quarters · filed 2026-08-04 | $6.70M derived: sum of 4 quarters · filed 2026-08-04 |
| 2025-03-31 | $1.80M 10-Q · filed 2026-05-05 | $3.30M derived: sum of 2 quarters · filed 2026-05-05 | $4.90M derived: sum of 3 quarters · filed 2026-05-05 | $6.50M derived: sum of 4 quarters · filed 2026-05-05 |
| 2024-12-31 | $1.50M derived: 10-K 12 month − 10-Q 9 month · filed 2025-02-21 | $3.10M derived: sum of 2 quarters · filed 2025-02-21 | $4.70M derived: sum of 3 quarters · filed 2025-02-21 | $6.50M 10-K · filed 2025-02-21 |
| 2024-09-30 | $1.60M 10-Q · filed 2024-10-31 | $3.20M derived: sum of 2 quarters · filed 2024-10-31 | $5.00M 10-Q · filed 2024-10-31 | $6.50M derived: sum of 4 quarters · filed 2024-10-31 |
| 2024-06-30 | $1.60M 10-Q · filed 2024-08-06 | $3.40M 10-Q · filed 2024-08-06 | $4.90M derived: sum of 3 quarters · filed 2024-08-06 | $6.50M derived: sum of 4 quarters · filed 2024-08-06 |
| 2024-03-31 | $1.80M 10-Q · filed 2024-05-01 | $3.30M derived: sum of 2 quarters · filed 2024-05-01 | $4.90M derived: sum of 3 quarters · filed 2024-05-01 | $6.60M derived: sum of 4 quarters · filed 2024-05-01 |
| 2023-12-31 | $1.50M derived: 10-K 12 month − 10-Q 9 month · filed 2024-02-22 | $3.10M derived: sum of 2 quarters · filed 2024-02-22 | $4.80M derived: sum of 3 quarters · filed 2024-02-22 | $6.50M 10-K · filed 2024-02-22 |
| 2023-09-30 | $1.60M 10-Q · filed 2023-11-01 | $3.30M derived: sum of 2 quarters · filed 2023-11-01 | $5.00M 10-Q · filed 2023-11-01 | $6.50M derived: sum of 4 quarters · filed 2023-11-01 |
| 2023-06-30 | $1.70M 10-Q · filed 2023-08-01 | $3.40M 10-Q · filed 2023-08-01 | $4.90M derived: sum of 3 quarters · filed 2023-08-01 | $6.50M derived: sum of 4 quarters · filed 2023-08-01 |
| 2023-03-31 | $1.70M 10-Q · filed 2023-05-02 | $3.20M derived: sum of 2 quarters · filed 2023-05-02 | $4.80M derived: sum of 3 quarters · filed 2023-05-02 | $6.40M derived: sum of 4 quarters · filed 2023-05-02 |
| 2022-12-31 | $1.50M derived: 10-K 12 month − 10-Q 9 month · filed 2023-02-16 | $3.10M derived: sum of 2 quarters · filed 2023-02-16 | $4.70M derived: sum of 3 quarters · filed 2023-02-16 | $6.50M 10-K · filed 2023-02-16 |
| 2022-09-30 | $1.60M 10-Q · filed 2022-11-01 | $3.20M derived: sum of 2 quarters · filed 2022-11-01 | $5.00M 10-Q · filed 2022-11-01 | $6.30M derived: sum of 4 quarters · filed 2022-11-01 |
| 2022-06-30 | $1.60M 10-Q · filed 2022-08-02 | $3.40M 10-Q · filed 2022-08-02 | $4.70M derived: sum of 3 quarters · filed 2022-08-02 | $6.00M derived: sum of 4 quarters · filed 2022-08-02 |
| 2022-03-31 | $1.70M 10-Q · filed 2022-05-04 | $3.10M derived: sum of 2 quarters · filed 2022-05-04 | $4.40M derived: sum of 3 quarters · filed 2022-05-04 | $5.90M derived: sum of 4 quarters · filed 2022-05-04 |
| 2021-12-31 | $1.40M derived: 10-K 12 month − 10-Q 9 month · filed 2022-02-16 | $2.70M derived: sum of 2 quarters · filed 2022-02-16 | $4.20M derived: sum of 3 quarters · filed 2022-02-16 | $5.70M 10-K · filed 2022-02-16 |
| 2021-09-30 | $1.30M 10-Q · filed 2021-11-02 | $2.80M derived: sum of 2 quarters · filed 2021-11-02 | $4.30M 10-Q · filed 2021-11-02 | $5.50M derived: sum of 4 quarters · filed 2021-11-02 |
| 2021-06-30 | $1.50M 10-Q · filed 2021-07-30 | $3.00M 10-Q · filed 2021-07-30 | $4.20M derived: sum of 3 quarters · filed 2021-07-30 | $5.50M derived: sum of 4 quarters · filed 2021-07-30 |
| 2021-03-31 | $1.50M 10-Q · filed 2021-05-04 | $2.70M derived: sum of 2 quarters · filed 2021-05-04 | $4.00M derived: sum of 3 quarters · filed 2021-05-04 | $5.30M derived: sum of 4 quarters · filed 2021-05-04 |
| 2020-12-31 | $1.20M derived: 10-K 12 month − 10-Q 9 month · filed 2021-02-12 | $2.50M derived: sum of 2 quarters · filed 2021-02-12 | $3.80M derived: sum of 3 quarters · filed 2021-02-12 | $5.20M 10-K · filed 2021-02-12 |
| 2020-09-30 | $1.30M 10-Q · filed 2020-10-29 | $2.60M derived: sum of 2 quarters · filed 2020-10-29 | $4.00M 10-Q · filed 2020-10-29 | $5.10M derived: sum of 4 quarters · filed 2020-10-29 |
| 2020-06-30 | $1.30M 10-Q · filed 2020-07-31 | $2.70M 10-Q · filed 2020-07-31 | $3.80M derived: sum of 3 quarters · filed 2020-07-31 | $4.90M derived: sum of 4 quarters · filed 2020-07-31 |
| 2020-03-31 | $1.40M 10-Q · filed 2020-04-30 | $2.50M derived: sum of 2 quarters · filed 2020-04-30 | $3.60M derived: sum of 3 quarters · filed 2020-04-30 | $4.70M derived: sum of 4 quarters · filed 2020-04-30 |
| 2019-12-31 | $1.10M derived: 10-K 12 month − 10-Q 9 month · filed 2020-02-14 | $2.20M derived: sum of 2 quarters · filed 2020-02-14 | $3.30M derived: sum of 3 quarters · filed 2020-02-14 | $4.50M 10-K · filed 2020-02-14 |
| 2019-09-30 | $1.10M 10-Q · filed 2019-10-31 | $2.20M derived: sum of 2 quarters · filed 2019-10-31 | $3.40M 10-Q · filed 2019-10-31 | $4.30M derived: sum of 4 quarters · filed 2019-10-31 |
| 2019-06-30 | $1.10M 10-Q · filed 2019-08-01 | $2.30M 10-Q · filed 2019-08-01 | $3.20M derived: sum of 3 quarters · filed 2019-08-01 | $4.00M derived: sum of 4 quarters · filed 2019-08-01 |
| 2019-03-31 | $1.20M 10-Q · filed 2019-05-01 | $2.10M derived: sum of 2 quarters · filed 2019-05-01 | $2.90M derived: sum of 3 quarters · filed 2019-05-01 | |
| 2018-12-31 | $900.00K derived: 10-K 12 month − 10-Q 9 month · filed 2019-02-15 | $1.70M derived: sum of 2 quarters · filed 2019-02-15 | $3.60M 10-K · filed 2019-02-15 | |
| 2018-09-30 | $800.00K 10-Q · filed 2018-11-01 | $2.70M 10-Q · filed 2018-11-01 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Lantheus Holdings, Inc. (LNTH) | United States | $6.510B | 26.31 |
| NEOGEN CORP (NEOG) | United States | $2.979B | -247.49 |
| Celldex Therapeutics, Inc. (CLDX) | United States | $2.471B | -9.72 |
| Intellia Therapeutics, Inc. (NTLA) | United States | $1.705B | -5.92 |
| ACHIEVE LIFE SCIENCES, INC. (ACHV) | United States | $0.806B | -5.88 |
| QuidelOrtho Corp (QDEL) | United States | $0.733B | -0.90 |
| Alpha Teknova, Inc. (TKNO) | United States | $0.500B | -18.12 |
| MYRIAD GENETICS INC (MYGN) | United States | $0.397B | -4.84 |
| Insight Molecular Diagnostics Inc. (IMDX) | United States | $0.129B | -3.90 |
| IMMUCELL CORP /DE/ (ICCC) | United States | $0.091B | 116.10 |